David Cohen, MD
Gastroenterology · Boston, MANPI 1881650133
Payments from drug & device makers
Across 30 payments — averaging $1327.99 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Esperion Therapeutics, Inc.$20K
- Pfizer$9K
- Astrazeneca UK Limited$4K
- Novo Nordisk$3K
- Boehringer Ingelheim$3K
- Regeneron$1K
- plus $635 from 6 others
Across 28 payments — averaging $817.07 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Ipsen Bioscience Inc.$11K
- Amryt Pharma Holdings Ltd$5K
- PTC Therapeutics, Inc.$5K
- Chiesi USA, Inc.$3K
What the payments were for
- Consulting fees$39,13398%
- Travel & lodging$430%
- Food & beverage$6642%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Esperion Therapeutics, Inc. | 7 | $19,602 |
| Pfizer | 5 | $8,500 |
| Astrazeneca UK Limited | 3 | $4,461 |
| Novo Nordisk | 1 | $2,713 |
| Boehringer Ingelheim | 1 | $2,620 |
| Regeneron | 2 | $1,310 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $181 |
| Sun Pharmaceutical Industries Inc. | 2 | $153 |
| Madrigal Pharmaceuticals | 1 | $132 |
| Medtronic | 1 | $93 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 3 | $48 |
| QOL Medical, LLC | 1 | $28 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- NEXLETOL$11,970
- NEXLIZET$11,970
- LEVULAN KERASTICK$135
- ILUMYA$135
- ABSORICA LD$135
- ODOMZO$135
- BLU-U$135
- REZDIFFRA$132
How this compares
$39,840 in reported general payments places this provider in the 85th percentile of 579 gastroenterology providers in Massachusetts.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other gastroenterology in Boston
- Ramnik XavierBoston$14.3M
- Scott SnapperBoston$4.9M
- Jessica AllegrettiBoston$3.3M
- John LeungBoston$2.8M
- Michael DouganBoston$2M
- Raymond ChungBoston$1.4M
- Kathleen CoreyBoston$1.4M
- Joshua KorzenikBoston$1.2M
- Hiroyuki AiharaBoston$988K
- Carlo TraversoBoston$987K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.